Drug intelligence / Profile preview

CW-3308

Development stage: Unknown
Lead developer: University of Michigan
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

CW-3308: sourced facts only. name: "Further optimization led to the discovery of CW-3308 as a potent, selective, and orally bioavailable BRD9 degrader." [PMID:39132814]; target: "Further optimization led to the discovery of CW-3308 as a potent, selective, and orally bioavailable BRD9 degrader." [PMID:39132814]; developer: "Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States." [PMID:39132814]; modality: "Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9." [PMID:39132814]

Targets

BRD9 (Bromodomain-containing protein 9)

Beyond the preview

Go deeper on CW-3308.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CW-3308.